A breakthrough in understanding pediatric drug-resistant epilepsy emerges from laboratory-grown brain tissue that mimics the exact genetic defects driving this devastating condition. The research addresses a critical gap in epilepsy science by creating the first functional model of how specific genetic mutations cause focal cortical dysplasia type II, which affects thousands of children worldwide who fail to respond to standard treatments.
Scientists engineered human cortical organoids—miniature brain structures grown from patient cells—with precise deletions in the DEPDC5 gene, which normally restrains the mTOR cellular growth pathway. When both copies of DEPDC5 were eliminated in a mosaic pattern, the organoids developed hyperactive mTOR signaling and produced malformed neurons with abnormal electrical activity, directly replicating the brain abnormalities seen in affected children. Treatment with rapamycin, an mTOR inhibitor, reversed these pathological changes.
The organoid model reveals previously unknown mechanisms underlying this epilepsy form. Single-cell analysis across developmental stages showed that DEPDC5 loss triggers premature neuron formation and disrupts critical Notch and Wnt signaling cascades that guide normal brain architecture. The affected neurons exhibited altered metabolism and protein synthesis, explaining why they become hyperexcitable and seizure-prone.
This represents a significant advance beyond previous animal models that failed to capture human-specific brain development patterns. The organoid platform enables systematic testing of targeted therapies, potentially identifying more effective treatments for children whose seizures resist conventional medications. However, the model's complexity and the rarity of suitable patient samples currently limit broader research applications. The work confirms that both genetic hits are essential for disease development, refining therapeutic targets.